Devyser Diagnostics

Devyser Diagnostics EBITDA per Share

The EBITDA per Share of Devyser Diagnostics (DVYSR.ST) as of Oct 27, 2026 is 0.63 SEK. In the previous year, EBITDA per Share was -3.51 SEK — a change of -118.09% (higher).

EBITDA per Share

0.63SEK

YoY

-118.09%

Last updated:

EBITDA per Share of Devyser Diagnostics is 2025 0.63 SEK. EBITDA per Share of Devyser Diagnostics was 2024 -3.51 SEK. It decreases by -118.09% higher compared to the previous year.

The Devyser Diagnostics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-1.17 SEK
Jan 1, 2019
2.85 SEK
Jan 1, 2020
-2.40 SEK
Jan 1, 2021
-1.89 SEK
Jan 1, 2022
-3.41 SEK
Jan 1, 2023
-3.47 SEK
Jan 1, 2024
-3.51 SEK
Jan 1, 2025
0.63 SEK
The Devyser Diagnostics EBITDA per Share history
YEAREBITDA per ShareYoY
0.63SEK-118.09%
-3.51SEK+1.12%
-3.47SEK+1.80%
-3.41SEK+80.61%
-1.89SEK-21.27%
-2.40SEK-184.09%
2.85SEK-343.86%
-1.17SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB develops and sells genetic testing kits for routine diagnostics, targeting hereditary diseases, oncology, and post-transplantation monitoring. The company offers products like Devyser Thrombophilia assay and Devyser Resolution XY, which analyze DNA for diagnosing genetic conditions and guiding cancer treatment. These kits are sold directly to end customers or through hired distributors across more than 45 countries, with nearly 30 products developed since inception. The firm generates revenue through direct sales and distributor partnerships, focusing on healthcare providers and laboratories that require genetic testing solutions. Its products are used in complex DNA analysis for diagnosing hereditary disorders and optimizing cancer therapies, serving a global market in over 45 countries without relying on third-party brands or external partnerships beyond its own product portfolio. Devyser Diagnostics AB's business model centers on selling its proprietary genetic testing kits, with no mention of additional services or third-party collaborations. The company's revenue streams are derived solely from product sales, targeting healthcare institutions that utilize DNA testing for diagnostic and therapeutic purposes in specialized medical fields. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

EBITDA per Share of Devyser Diagnostics is 0.63 SEK in 2025.

EBITDA per Share of Devyser Diagnostics changed from -3.51 SEK to 0.63 SEK, representing a -118.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics